NewsRoom Articles - Page 193 of 193

FridayMar 15, 2019 12:40 pm

Genprex Inc. (NASDAQ: GNPX) Employs Trademarked Gene Therapy in Team-up to Fight Lung Cancer

Lung cancer is one of the most commonly occurring tumors in men and women, and it is the common cancer that’s most likely to result in death among all U.S. populations Genprex is advancing its trademarked Oncoprex immunogene therapy as a means of bolstering the body’s protein defenses against lung tumor growth Clinical trials for Oncoprex are evaluating ways to team it with other targeted therapies and immunotherapies to increase the overall efficacy of the therapies The war on deadly cancers continues to advance innovative developments in the field of targeted therapies that block the growth of cancer cells by…

TuesdayMar 12, 2019 9:00 am

Making Profits, Saving Lives with Gene Therapy

BioMedWire Editorial Coverage: After thirty years of development, gene therapy is seeing a surge of progress and profitability. Gene therapies tackle diseases by altering the genetic makeup of patients’ cells. Recent mergers and research developments make this a promising time to invest in the sector. Gene therapy companies are developing treatments for everything from cancer and HIV to skin diseases. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is developing treatments to tackle lung cancer. Spark Therapeutics Inc. (NASDAQ: ONCE), which recently entered a merger agreement with the Roche Group, targets ailments such as retinal and neurodegenerative diseases. Dyadic International Inc. (OTCQX:…

WednesdayDec 05, 2018 1:30 pm

Genprex, Inc. (GNPX) Starts Presentation at LD Micro Main Event

Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex™ has also been shown to block mechanisms that create drug resistance. For more information, visit the company's website at www.genprex.com…

TuesdayJun 05, 2018 6:00 pm

Genprex, Inc. (NASDAQ: GNPX) Starts Presentation at the 8th Annual LD Micro Invitational

Genprex, Inc. (NASDAQ: GNPX) is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (“NSCLC”). Genprex's platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. For more information, visit the company's website at www.Genprex.com. About BioMedWire BioMedWire (BMW) is an information service that provides…